HomeCompareWGNR vs ABBV

WGNR vs ABBV: Dividend Comparison 2026

WGNR yields 14184.40% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 WGNR wins by $1741245461664930048.00M in total portfolio value
10 years
WGNR
WGNR
● Live price
14184.40%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1741245461664930048.00M
Annual income
$1,717,427,461,345,424,000,000,000.00
Full WGNR calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — WGNR vs ABBV

📍 WGNR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodWGNRABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, WGNR + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
WGNR pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

WGNR
Annual income on $10K today (after 15% tax)
$1,205,673.76/yr
After 10yr DRIP, annual income (after tax)
$1,459,813,342,143,610,500,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, WGNR beats the other by $1,459,813,342,143,610,500,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of WGNR + ABBV for your $10,000?

WGNR: 50%ABBV: 50%
100% ABBV50/50100% WGNR
Portfolio after 10yr
$870622730832465024.00M
Annual income
$858,713,730,672,712,000,000,000.00/yr
Blended yield
98.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

WGNR
No analyst data
Altman Z
-288.0
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

WGNR buys
0
ABBV buys
0
No recent congressional trades found for WGNR or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricWGNRABBV
Forward yield14184.40%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$1741245461664930048.00M$102.3K
Annual income after 10y$1,717,427,461,345,424,000,000,000.00$24,771.77
Total dividends collected$1739668430966621440.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: WGNR vs ABBV ($10,000, DRIP)

YearWGNR PortfolioWGNR Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,429,140$1,418,439.72$11,550$430.00+$1.42MWGNR
2$190,982,313$189,453,134.00$13,472$627.96+$190.97MWGNR
3$23,865,535,334$23,661,184,258.31$15,906$926.08+$23865.52MWGNR
4$2,788,853,260,935$2,763,317,138,127.58$19,071$1,382.55+$2788853.24MWGNR
5$304,771,704,176,462$301,787,631,187,262.06$23,302$2,095.81+$304771704.15MWGNR
6$31,148,518,911,483,350$30,822,413,188,014,540.00$29,150$3,237.93+$31148518911.45MWGNR
7$2,977,381,874,110,252,500$2,944,052,958,874,965,500.00$37,536$5,121.41+$2977381874110.22MWGNR
8$266,187,755,143,456,800,000$263,001,956,538,158,780,000.00$50,079$8,338.38+$266187755143456.72MWGNR
9$22,259,813,382,715,685,000,000$21,974,992,484,712,187,000,000.00$69,753$14,065.80+$22259813382715684.00MWGNR
10$1,741,245,461,664,930,200,000,000$1,717,427,461,345,424,000,000,000.00$102,337$24,771.77+$1741245461664930048.00MWGNR

WGNR vs ABBV: Complete Analysis 2026

WGNRStock

Wegener Corporation, through its subsidiary, Wegener Communications, Inc., designs, manufactures, and distributes satellite communications electronics equipment in the United States and internationally. The company offers iPump media servers, which receives and stores television, radio, and other digital files from broadcast, cable, and business network operations; Compel Network Control and Compel Conditional Access for dynamic command, monitoring, and addressing multi-site video, audio, and data networks; and Nielsen Media Research products, such as NAVE IIc and SpoTTrac encoders, which are used to encode Nielsen Media Research identification tags into media for Nielsen program ratings, as well as MediaPlan network control and content management products, which provides digital asset management in an end-to-end multi-site environment. It also provides Unity satellite media receivers, including Unity 552 for private and business television networks; Unity 4600, a digital satellite receiver that is used primarily by program originators to distribute analog and digital programming; and Unity 202 audio receiver for business music providers. In addition, the company offers digital television digital stream processors for cable and telecom headends allowing them to integrate local off-air high definition broadcast television channels and digital programs, and insert them onto their networks; uplink equipment for video and audio distribution; and customized products. It serves business and private networks, broadcast television and program originators, and radio broadcasters through direct sales force, sales representatives, value added resellers, integrators, and independent distributors. The company was founded in 1977 and is headquartered in Johns Creek, Georgia. As of December 29, 2017, Wegener Corporation operates as a subsidiary of Novra Technologies Inc.

Full WGNR Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this WGNR vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

WGNR vs SCHDWGNR vs JEPIWGNR vs OWGNR vs KOWGNR vs MAINWGNR vs JNJWGNR vs MRKWGNR vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.